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Abstract
Mice lacking surfactant protein A (SP-A) mRNA and protein in vivo were generated using gene targeting techniques. SP-A
(3/3) mice have normal levels of SP-B, SP-C and SP-D mRNA and protein and survive and breed normally in vivarium
conditions. Phospholipid composition, secretion and clearance, and incorporation of phospholipid precursors are normal in
the SP-A (3/3) mice. Lungs of SP-A (3/3) mice have markedly decreased tubular myelin figures and clear Group B
streptococci and Pseudomonas aeruginosa less efficiently than SP-A wild type mice. These studies of SP-A (3/3) mice
demonstrate that SP-A has an important role in the innate immune system of the lung in vivo. ß 1998 Elsevier Science B.V.
All rights reserved.
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1. SP-A structure and synthesis
SP-A is an abundant pulmonary surfactant asso-
ciated protein encoded by two genes in the human
and a single gene in the mouse [1,2]. The primary
translation product generated from the SP-A
mRNAs encodes a leader sequence which is cleaved
during processing, an N-terminal collagen-like do-
main, a hydrophobic neck domain, and a C-termi-
nal C-type lectin domain [3]. The mature peptide
forms trimers that assemble to form an octadecamer
that is the predominant airway form [4]. SP-A binds
various lipids and glycolipids including dipalmit-
oylphosphatidylcholine (DPPC) and binds to
surface receptors on type II cells and macrophages
[5^9]. SP-A synthesis is initiated in the distal
developing epithelium and remains in the type II
cells, Clara cells, and subsets of cells in tracheo-
bronchial glands in the adult [10]. SP-A levels are
reduced during oxygen injury, viral injury, and
in pneumonia caused by viruses and bacteria [11^
13].
2. SP-A and surfactant homeostasis
2.1. In vitro studies
The structure, function and regulation of SP-A
have been extensively studied in vitro (see also the
chapter by McCormack). SP-A enhanced the uptake
of phospholipids and decreased phospholipid secre-
tion in type II cells in vitro [14,15]. SP-A binds and
aggregates lipids in a calcium dependent manner, en-
hances surface adsorption of phospholipids, protects
surface activity of phospholipids from protein inhib-
ition [16^18] and enhances formation of tubular mye-
lin in vitro [19]. Recent £uorescence studies demon-
strated that SP-A, in the presence of calcium,
aggregated surfactant lipids and proteins on the cell
surface and inhibited intracellular uptake of surfac-
tant [20]. Since phospholipid metabolism is only min-
imally altered in the SP-A (3/3) mouse model, the
role of SP-A in regulating phospholipid levels in vivo
is unclear.
3. SP-A and host defense
3.1. SP-A is a collectin
SP-A is a member of a larger family of polypep-
tides termed collectins. The collectins are a family of
multimeric proteins that form larger oligomeric
structures via NH2-terminal and collagen-like do-
mains [21]. SP-A and other members of the collectin
family, including mannose binding protein (MBP)
and surfactant protein D (SP-D) map to the long
arm of human chromosome 10 and share similar in-
tron-exon organization, suggesting that they arose by
duplications of a primordial gene [22,23]. MBP is
produced by the liver and secreted into the serum
and children carrying mutations in MBP are more
susceptible to recurrent infections [24], supporting
the concept that the collectins are part of the innate
immunity against microbial pathogens.
3.2. SP-A enhances bacterial phagocytosis in vitro
In vitro studies support a role for SP-A in enhanc-
ing microbial phagocytosis by macrophages by (1)
acting as an opsonin or (2) directly stimulating mac-
rophages (Table 1) (see also the chapter by Haags-
man). SP-A binds some but not all bacteria. SP-A
binds some strains of Streptococcus pneumoniae and
Staphylococcus aureus ; Haemophilus in£uenzae type a
and non-typed; and Escherichia coli J5 [25^30]. It
does not bind E. coli 0111 or K12; or some strains
of S. aureus or P. aeruguinosa [29^32]. It weakly
binds H. in£uenzae type b [28]. SP-A opsonization
of S. aureus, E. coli J5 and S. pneumoniae enhances
their phagocytosis by macrophages [25^27,30,31].
SP-A also stimulates phagocytosis of E. coli K12
and P. aeruginosa independently of opsonization
[31,32]. SP-A enhances phagocytosis of serum opson-
ized S. aureus by macrophages [33]. SP-A enhances
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macrophage phagocytosis of Klebsiella pneumoniae
and Mycobacterium by increasing activity of the
mannose receptor thereby enhancing bacterial bind-
ing and uptake [34,35]. SP-A also binds Herpes sim-
plex type I infected cells [36], in£uenza A [37] and
Pneumocystis carinii [38,39]. The structure of SP-A
and activity of SP-A in vitro strongly supports a
role of SP-A in clearance of microbial pathogens
from the lung as part of the innate immunity.
4. SP-A gene-targeted mice
4.1. SP-A gene targeting
Homologous recombination in embryonic stem
(ES) cells was used to generate a null mutation of
the SP-A locus [40]. The SP-A gene was cloned from
strain 129J, its sequence determined, and a targeting
construct generated by replacement of a portion of
exon 3, intron 3 and exon 4 with pGKneoBpA (Fig.
1). The targeting construct was electroporated into
ES14.1 cells and correctly targeted cells were selected
by double selection with G418 and gancyclovir. The
correctly targeted allelic mutation contained a strong
alternative promoter (pGK), a strong polyadenyla-
tion signal, and lacked sequences encoding a major
portion of the collagen-like domain. Chimeric mice
were bred to generate heterozygotic mice (+/3) car-
rying one copy of the targeted allele. Homozygote
o¡spring lacking SP-A (SP-A 3/3) were produced
from mating the heterozygotes. The distribution of
genotypes followed a Mendelian inheritance pattern
[40], indicating that the targeted SP-A allele did not
cause unanticipated fetal losses. Homozygote (SP-A
3/3) targeted mice lacked SP-A mRNA and protein
but survived normally in the vivarium. Body weight,
lung weight, and lung DNA concentration did not
di¡er between SP-A (+/+) and SP-A (3/3) mice
studied at 8 weeks and 8 months of age [41].
Fig. 1. SP-A targeting construct. The mouse SP-A gene locus is diagrammed on the top line with positions of exons marked and num-
bered as closed boxes. The position of HindIII sites used to generate the targeting vector are depicted with an asterisk. Portions of
exon 3 and exon 4 and all of intron 3 including splice junctions were replaced by the replacement vector, pGKneoBpA [40].
Table 1
Role of SP-A in bacterial clearance in vitro
Bacteria Binds SPA in vitro SPA enhanced attachment and/or phagocytosis
by macrophages, in vitro
SPA enhanced killing
in vitro
Group B Streptococcus Yes Yes ^
P. aeruginosa No [25,31,32] Yes [31,32] ^
S. pneumonia, not typed Yes [25,27] Yes [25] ^
S. pneumonia, type 25 Yes [27] No [27] ^
H. in£uenza, type a Yes [28] Yes [28] Yes [28]
H. in£uenza, type b Weakly [28] No [28] No [28]
H. in£uenza, not typed Yes [25] Yes [25] ^
S. aureus Yes [26,27] Yes [26,27,31,32,34] No [26,27]
No [31,32] ^
E. coli J5 Yes [29,30] Yes [30] Yes [30]
E. coli 0111 No [29,30] ^ ^
E. coli K12 No [31,32] Yes [31,32] ^
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4.2. Surfactant proteins and phospholipids in SP-A
(3/3) mice
Lung SP-A mRNA and protein content were re-
duced approx. 50% in heterozygote SP-A (+/3) mice,
demonstrating the critical role of SP-A gene dosage
in the regulation of SP-A synthesis. SP-B, C, and D
mRNAs and protein levels were assessed in SP-A
(3/3) mice by Northern and S1 nuclease analysis
and Western blots. No detectable di¡erences in
mRNA or protein levels were observed in SP-A
(+/+), (+/3) and (3/3) mice, indicating that there
are no compensatory changes in other surfactant
proteins in the absence of SP-A [40].
Surfactant phospholipid pool sizes were compared
in SP-A (+/+) and (3/3) mice. Saturated phospha-
tidylcholine levels were slightly higher in alveolar
washes and tissues of SP-A (3/3) mice at 8 weeks
and 8 months of age [41]. There were no di¡erences
in phospholipid composition [40]. The small changes
in phospholipid pool sizes had no appreciable e¡ect
on survival of SP-A (3/3) mice housed in pathogen
free containment.
4.3. Surfactant metabolism in SP-A (3/3) mice
The incorporation of radiolabeled palmitic acid
and choline into saturated phosphatidylcholine was
assessed following intratracheal instillation. Incorpo-
ration of radiolabeled palmitic acid and choline into
saturated phosphatidylcholine was virtually identical
in SP-A (3/3) and SP-A (+/+) mice. Incorporation
of radiolabeled phospholipid precursors were slightly
greater in SP-A (3/3) mice 48 h after instillation.
This time period re£ects synthesis, secretion and re-
uptake suggesting that SP-A may have a small e¡ect
on reuptake in vivo. The rate of phosphatidylcholine
synthesis, assessed by incorporation of radiolabeled
precursors into saturated phosphatidylcholine in lung
slices of SP-A (+/+) and (3/3) mice, were identical.
Secretion of radiolabeled phosphatidylcholine pre-
cursors also did not di¡er between genotypes. Clear-
ance of radiolabeled dipalmitoyl phosphatidylcholine
(DPPC) was similar from lungs of SP-A (+/+) and
(3/3) mice, ranging from 9.4 to 11.2 h. Likewise,
clearance of radiolabeled SP-B from lungs of SP-A
(+/+) and (3/3) mice was nearly identical [41]. The
clearance rate of radiolabeled SP-A was signi¢cantly
lower in SP-A (3/3) mice (approx. 10.2 h in +/+
compared to 14.5 h in 3/3 mice) [42].
4.4. Properties of surfactant from SP-A (3/3) mice
Surface tension lowering properties of isolated sur-
factant from SP-A (3/3) and SP-A (+/+) mice were
assessed at various phosphatidylcholine concentra-
Fig. 2. Minimal surface tension of isolated surfactant. Surfactant was isolated from 8^12 week old mice as previously described [40].
Minimal surface tension was measured on a Wilhelmy balance at 37‡C and is reported from the fourth cycle. At 0.01 Wmol/ml of sa-
turated PC but not at 0.25 Wmol/ml SP-A (3/3) produced a higher surface tension than SP-A (+/+) surfactant. In the presence of
0.4 or 0.8 mg/ml of plasma protein, minimum surface tension produced by SP-A (3/3) surfactant was signi¢cantly greater than pro-
duced by SP-A (+/+) surfactant [42].
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tions with the Wilhelmy balance. In the presence of
calcium, surface tension lowering properties of iso-
lated surfactant from SP-A (3/3) and SP-A (+/+)
surfactant was similar. In contrast, in the absence
of calcium, reduction of surface tension by SP-A
3/3 surfactant, at low phosphatidylcholine concen-
trations was reduced. Signi¢cant di¡erences were
only detected at phospholipid concentrations approx.
3 orders of magnitude lower than that present in the
lung [40]. This ¢nding supports the concept that
SP-A may improve surfactant function in conditions
associated with reduced phosphatidylcholine levels
(Fig. 2).
Conversion of surfactant from large to small ag-
gregate forms di¡ered between SP-A (+/+) and SP-A
(3/3) mice. During mechanical cycling, conversion
from large to small aggregates was 7.3 þ 5.0% for SP-
A (3/3) mice compared to 37.0 þ 3.0% for wild type
mice [42]. Surfactant from SP-A (+/+) mice con-
tained 48 þ 1% large aggregates compared to
15 þ 2% for SP-A (3/3) mice. Large aggregate sur-
factant from SP-A (3/3) and SP-A (+/+) mice in-
creased thoracic compliance when delivered to venti-
lated preterm rabbits to the same extent and resulted
in similar maximal lung volume at 30 cm H2O. De-
spite detectable di¡erences in conversion rates of
large aggregate surfactant fractions between (3/3)
and (+/+) mice, both were equally e¡ective in restor-
ing lung function in neonatal preterm rabbits.
Adsorption rates of isolated surfactant from (+/+)
and (3/3) mice were similar. In the presence of plas-
ma protein concentrations greater than 0.4 mg/ml,
surface tension reducing properties of SP-A (3/3)
surfactant were markedly reduced compared to
surfactant from SP-A (+/+) mice (Fig. 2), con¢rming
previous studies demonstrating that SP-A protects
surfactant from inactivation by serum proteins
[42].
4.5. Lack of tubular myelin from SP-A (3/3) mice
To assess the structure and abundance of tubular
myelin, lung sections were examined by electron mi-
croscopy. Forty ¢elds from SP-A (+/+) contained 15
large tubular myelin ¢gures whereas 70 ¢elds from
SP-A (3/3) lungs contained only two small tubular
myelin ¢gures [40]. Although abundant tubular mye-
lin ¢gures were readily detected in large aggregate
surfactant isolated from SP-A (+/+) mice, tubular
myelin was not detected in pellets from SP-A
(3/3) mice, supporting previous in vitro ¢ndings
that SP-A contributed to tubular myelin formation.
The markedly decreased tubular myelin ¢gures in
SP-A (3/3) mice strongly suggest that tubular mye-
lin is not required for pulmonary surfactant homeo-
stasis or function in vivo.
Table 2
Decreased clearance of Group B beta hemolytic Streptococcus in SP-A (3/3) mice
Time (h) SP-A (3/3) SP-A (+/+) n
6 4.5U105 þ 2.1U105* 6.2U103 þ 5.4U103 10
24 6.3U104 þ 3.8U104* 1.1U103 þ 9.8U102 10
48 9.9U104 þ 3.3U104* 4.6U104 þ 4.1U104 10
Quantitative cultures of lung homogenates were performed 6, 24 and 48 h after trans-tracheal inoculation of the animals with 104 col-
ony forming units of GBS. Data are reported as bacterial colonies/g of lung and are means þ S.E.M. for n animals, *P6 0.05 com-
pared to SP-A (+/+) mice using the median scores non-parametric test.
Table 3
Decreased clearance of P. aeruginosa in SP-A (3/3) mice
Time (h) SP-A (3/3) SP-A (+/+) n
6 2.5U108 þ 7.8U107* 8.3U107 þ 3.6U107 10
24 1.3U107 þ 7.4U106* 3.7U105 þ 2.4U105 10
48 1.9U105 þ 1.0U105 1.1U106 þ 9.3U105 10
Quantitative cultures of lung homogenates were performed 6, 24 and 48 h after trans-tracheal inoculation of the animals with 108 col-
ony forming units of P. aeruginosa. Data are reported as bacterial colonies/g of lung and are means þ S.E.M. for n animals, *P6 0.05
compared to SP-A (+/+) mice using the median scores non-parametric test.
BBADIS 61779 2-11-98
T.R. Korfhagen et al. / Biochimica et Biophysica Acta 1408 (1998) 296^302300
5. SP-A (3/3) mice are susceptible to lung infection
5.1. Clearance of Group B beta hemolytic streptococci
Group B beta hemolytic streptococci (GBS) are
common pathogens in premature and term neonates.
To determine whether SP-A protects the lung from
GBS in vivo, SP-A (3/3) and (+/+) mice were in-
fected with GBS by tracheal injection. Clearance of
GBS from the lungs of SP-A (3/3) mice was signi¢-
cantly reduced compared to SP-A (+/+) mice (Table
2). Moreover GBS proliferated in the lungs of SP-A
(3/3) mice and was detectable in the spleen at 24
and 48 h. Lack of SP-A increased pulmonary bacte-
rial infection and permitted septic spread in the GBS
mouse model [43]. When GBS was premixed with
SP-A (100 or 150 Wg/104 bacteria), clearance was as
e⁄cient as in SP-A (+/+) mice [44]. Recently, SP-A
was found to bind to GBS in the presence of calcium
suggesting that SP-A acts as an opsonin for GBS
(J.R. Wright, personal communication).
Decreased GBS clearance was associated with de-
creased binding and uptake of the organisms by al-
veolar macrophages. Fewer macrophages contained
ingested bacteria from the SP-A (3/3) than from the
SP-A (+/+) mice 6 h post infection. Oxygen radical
production by the alveolar macrophages was mark-
edly reduced in SP-A (3/3) mice [44]. SP-A increases
Group B strep clearance in vivo by enhancing mac-
rophage phagocytosis and by enhancing production
of microbiocidal free radicals.
5.2. Pseudomonas
To determine whether SP-A also enhances clear-
ance of Gram-negative bacteria, we determined clear-
ance rates of mucoid P. aeruginosa, a common pul-
monary pathogen in cystic ¢brosis and hospital
acquired pulmonary infection. Clearance of trache-
ally instilled P. aeruginosa was signi¢cantly reduced
in SP-A (3/3) compared to SP-A (+/+) mice in vivo
at 6 and 24 h post infection (Table 3). Macrophages
isolated 1^2 h post infection contained signi¢cantly
less Pseudomonas from SP-A (3/3) than SP-A (+/+)
mice. Free radical synthesis by polymorphonuclear
leukocytes did not di¡er in infected SP-A (+/+) and
(3/3) mice, demonstrating that SP-A enhanced free
radical synthesis by these cells is not critical to clear-
ance of mucoid Pseudomonas from the lung [45]. SP-
A does not bind to this P. aeruginosa in vitro so it is
likely that SP-A enhances phagocytosis of P. aerugi-
nosa in vivo by stimulating macrophage receptor ac-
tivity by a process independent of opsonization.
6. Concluding comments and perspectives
We have generated mice lacking SP-A to decipher
the role of pulmonary SP-A in vivo. Unlike a null
mutation of SP-B where mice die of an RDS syn-
drome immediately after birth [46], SP-A de¢cient
mice survive and breed normally. Phospholipid com-
position, incorporation of phospholipid precursors,
secretion of phosphatidylcholine, and clearance of
dipalmitoylphosphatidylcholine did not di¡er signi¢-
cantly between SP-A (+/+) and SP-A (3/3) mice.
Small increases in phospholipid pools and decreased
clearance of SP-A from SP-A (3/3) mice did not
signi¢cantly alter lung function in vivo. Lack of tub-
ular myelin ¢gures and susceptibility of isolated
SP-A (3/3) surfactant to protein inhibition in vitro
con¢rmed previous conclusions that SP-A is involved
in tubular myelin formation and in protection of
surfactant from protein inhibition. Reduced clear-
ance of Group B streptococci and P. aeruginosa sup-
ports the concept that SP-A plays an important role
in innate immunity, protecting the lung from micro-
bial infection and injury.
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